Longeveron LLC - Class A (LGVN) Stock Price

0.68 ▲ +0.0021 (+0.31%)
Open: 0.682 Vol: 0 Day's range: 0.68 - 0.70 Aug 11, 09:58 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
LGVN Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 0.68▼ 0.68▲ 0.76▼ 1.13▼ 1.24▼
MA10 0.68▼ 0.81▼ 0.99▼ 1.38▼ 1.27▼
MA20 0.67▲ 1.05▼ 1.21▼ 1.49▼ 1.35▼
MA50 0.85▼ 1.35▼ 1.46▼ 1.38▼ 1.64▼
MA100 1.17▼ 1.48▼ 1.56▼ 1.44▼ 5.01▼
MA200 1.38▼ 1.55▼ 1.47▼ 1.62▼ 31.71▼
  5 mins 30 mins Hourly Daily Weekly
MACD 0.019▲ -0.036▼ -0.066▼ -0.113▼ -0.021▼
RSI 35.111▼ 12.252▼ 8.996▼ 22.252▼ 32.345▼
STOCH 55.651     7.351▼ 4.753▼ 18.535▼ 46.162    
WILL %R -33.278     -92.563▼ -94.317▼ -95.830▼ -95.973▼
CCI 23.211     -65.854     -117.753▼ -238.823▼ -252.860▼
Latest Filters Detected On LGVN
▼ RSI&STOCH $LGVN Oversold RSI + Stochastic Set Alert
CDL $LGVN Harami Candlestick Pattern Detected Set Alert
CDL $LGVN Matching Low Candlestick Pattern Detected Set Alert
CDL $LGVN Doji Candlestick Pattern Detected Set Alert
Longeveron LLC - Class A News
Longeveron Announces Up To $17.5 Million Public Offering
Friday, August 08, 2025 10:47 AM
MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life ...
Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025
Tuesday, August 05, 2025 09:08 AM
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy ...
Monday, July 28, 2025 04:09 PM
Laromestrocel is a proprietary, scalable, allogeneic, investigational cellular therapy derived from mesenchymal stem cells (MSCs) with multiple potential mechanisms of action that may lead to ...
LGVN historical stock data
date open high low close volume
11/08/25 0.682 0.70 0.68 0.68 814,364
08/08/25 1.26 1.27 0.633 0.6779 8,598,913
07/08/25 1.52 1.52 1.26 1.27 501,710
06/08/25 1.58 1.58 1.4501 1.495 220,300
05/08/25 1.53 1.59 1.53 1.55 242,745
04/08/25 1.65 1.75 1.608 1.71 215,266
01/08/25 1.58 1.65 1.5501 1.635 121,103
31/07/25 1.58 1.665 1.55 1.62 162,929
30/07/25 1.57 1.63 1.54 1.58 105,396
29/07/25 1.70 1.70 1.54 1.56 190,833
Quote Details
52wk Low:0.633
52wk High:2.86
Vol:0
Avg Vol(3m):10.2M
1Y Chng:-71.78%
1M Chng:-47.69%
Add to Watch List
More Information
Index US Composite
Market Cap. 22.62M